Edition:
United States

GTX Inc (GTXI.OQ)

GTXI.OQ on NASDAQ Stock Exchange Capital Market

4.83USD
3:35pm EDT
Change (% chg)

$-0.11 (-2.23%)
Prev Close
$4.94
Open
$4.94
Day's High
$4.94
Day's Low
$4.81
Volume
9,279
Avg. Vol
4,707
52-wk High
$11.10
52-wk Low
$4.52

Latest Key Developments (Source: Significant Developments)

Gtx Inc qtrly loss per share $0.44
Wednesday, 15 Mar 2017 07:00am EDT 

Gtx Inc : Gtx provides corporate update and reports fourth quarter and year-end 2016 financial results . Gtx inc -expects to report preliminary results from its phase 2 clinical trial of enobosarm to treat stress urinary incontinence (sui) in q3 of 2017 . Gtx -xpects to begin an initial clinical study of selective androgen receptor degrader in men with castration-resistant prostate cancer in second half of 2017 . Gtx inc- as of december 31, 2016, cash and short-term investments were $21.9 million compared to $29.3 million at december 31, 2015 .Gtx inc qtrly loss per share $0.44.  Full Article

GTx says primary efficacy endpoint met in Enobosarm 9 mg cohort
Thursday, 8 Dec 2016 07:00am EST 

GTx Inc : Primary efficacy endpoint met in Enobosarm 9 mg cohort . Enobosarm 9 mg appears to be safe and generally well tolerated . Plans to report top-line clinical results following completion of clinical trial, which is anticipated to occur in mid-2017 . Trial will continue as planned with a daily dose of either Enobosarm 9 mg or 18 mg .GTx reports results from ongoing Enobosarm phase 2 clinical trial in er+/ar+ breast cancer.  Full Article

GTx achieves second stage 1 milestone in Phase 2 clinical trial
Wednesday, 16 Nov 2016 07:00am EST 

GTx Inc : Top line data from stage 1 of 9 mg cohort expected in December 2016 .GTx achieves second stage 1 milestone in phase 2 clinical trial of enobosarm in ER+/AR+ breast cancer.  Full Article

GTX qtrly loss per share $0.04
Tuesday, 9 Aug 2016 07:00am EDT 

Gtx Inc : Gtx provides corporate update and reports second quarter 2016 financial results .Qtrly loss per share $0.04.  Full Article

GTx reports Q1 earnings per share $0.01
Tuesday, 10 May 2016 07:00am EDT 

GTx Inc : GTx provides corporate update and reports first quarter 2016 financial results . Qtrly earnings per share $0.01 .Q1 earnings per share view $-0.04 -- Thomson Reuters I/B/E/S.  Full Article

GTx, Inc receives FDA clearance to initiate clinical trial in Stress Urinary Incontinence
Tuesday, 13 Oct 2015 07:00am EDT 

GTx, Inc:Receives FDA clearance to initiate clinical trial in stress urinary incontinence.Says trial to evaluate an orally administered sarm in postmenopausal women with stress urinary incontinence.Says preclinical data demonstrates a sarm can increase pelvic floor muscle mass and potentially improve outcomes in women with sui.Says company plans to initiate the trial by the first quarter of 2016 and anticipates top-line data later in 2016.Says FDA has accepted the company's investigational new drug (ind) application for a phase 2 clinical trial.  Full Article

GTx and the University of Tennessee Research Foundation enter into exclusive license agreement to develop UTRF's SARD Drug Technology
Thursday, 23 Apr 2015 07:00am EDT 

GTx Inc:Enters into an exclusive worldwide license agreement with the University of Tennessee Research Foundation (UTRF) to develop its proprietary selective androgen receptor degrader (SARD) technology which potentially can degrade and inhibit all forms of androgen receptor (AR).Including those resistant to current therapies, in patients with progressive castration-resistant prostate cancer (CRPC).  Full Article

More From Around the Web

BRIEF-Gtx Inc qtrly loss per share $0.44

* Gtx provides corporate update and reports fourth quarter and year-end 2016 financial results